Sunscreen Lotion (Y65-110)
PreclinicalSmall molecule
BayerSunscreen Lotion (Y65-110) is one of 6 small molecule programs targeting Ototoxicity. It is currently in Preclinical.
1
Indications
6
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Ototoxicity
#DrugCompanyPhaseTrials
1Qualaquin
Sun Pharmaceutical Industries, Inc.Approved
Bayer Aspirin
BayerPreclinical
Acetyl Cysteine
TTanta University
Phase 2
BAY987517
BayerPreclinical
SPF Control
BayerPreclinical
Sunscreen Lotion (Y65-110)
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sunscreen Lotion (Y65-110). EMBL-EBI & Wellcome Sanger Institute.
- [4]